Core Insights - Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors [1][3] - The company's lead program, ficerafusp alfa, targets both epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-β), aiming to provide significant anti-tumor activity [3] Company Presentation - Claire Mazumdar, CEO of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference on November 19, 2024, at 9:10 a.m. ET [1] - A live webcast of the presentation will be available on Bicara's website, with an archived replay accessible for approximately 90 days [2] Product Development - Ficerafusp alfa is being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [3]